Financial Personal
Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors
Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) — Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a ce
Based on Preliminary Data from Ongoing Dose Ranging Stage of the Phase 1/2 Clinical Trial Read More
Related
Share this page
Guest Posts by Easy Branches